Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP) / Q000235:genetics; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011110:Polymorphism, Genetic; D013607:Tablets; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
D013607:Tablets; D005641:Tegafur; D014498:Uracil; D000077146:Irinotecan; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP); D002955:Leucovorin; D002166:Camptothecin